NCT07107178View on ClinicalTrials.gov

A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

August 8, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

August 31, 2027

Conditions
Advanced MelanomaAdvanced Solid Tumor
Interventions
DRUG

BT02

monoclonal antibody injection with intravenous administration every 2 or 3 weeks

Sponsors
All Listed Sponsors
collaborator

Peking University Cancer Hospital and Institute

OTHER

lead

Biotroy Therapeutics

INDUSTRY